All treatments
Treatment
LIBTAYO 350 mg concentrate for solution for infusion. clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
This study is testing a new medicine, cemiplimab (also known as Libtayo), for a type of skin cancer called cutaneous squamous cell carcinoma. Doctors want to see if giving this medicine before surgery can completely clear the cancer cells at the original site.
For: Stage II to IV cutaneous squamous cell carcinomaGermany - AuthorisedTherapeutic exploratory (Phase II)
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.
This study is looking at how a medicine called cemiplimab (Libtayo) works in people with advanced skin cancer (cutaneous squamous cell carcinoma). Researchers want to understand why some people respond well and others don't, by studying blood and tumour samples.
For: Cutaneous squamous cell carcinoma (ccSCC)Spain